Evidence map›Paper›PMID 36839834›Full record

ArticlePharmaceutics2023

Montmorillonite-Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic.

Elmar Damasceno Junior, Raquel de Melo Barbosa, Rita de Cássia Dantas da Silva, Felipe Dos Santos Costa, Djalma Ribeiro da Silva, César Viseras, Luana Perioli, Nedja Suely Fernandes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Elmar Damasceno JuniorInstitute of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
Raquel de Melo BarbosaPharmaceutical Technology Department, University of Granada, 18071 Granada, Spain.ORCID 0000-0003-3798-5512
Rita de Cássia Dantas da SilvaInstitute of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
Felipe Dos Santos CostaInstitute of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
Djalma Ribeiro da SilvaInstitute of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
César ViserasPharmaceutical Technology Department, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-2219-3566
Luana PerioliDepartment of Pharmaceutic Science, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-3890-3283
Nedja Suely FernandesInstitute of Chemistry, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
Universidade Federal do Rio Grande do Norte · BRUniversidad de Granada · ESUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral 'montmorillonite' as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 2

Indexed as

montmorillonitenanohybridpH-responsive systemrifampicintuberculosis

Identifiers

PMID36839834
PMCPMC9966939
OpenAlexW4319081273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.